RS56121B1 - Novi derivati benzimidazola kao ep4-antagonisti - Google Patents
Novi derivati benzimidazola kao ep4-antagonistiInfo
- Publication number
- RS56121B1 RS56121B1 RS20170790A RSP20170790A RS56121B1 RS 56121 B1 RS56121 B1 RS 56121B1 RS 20170790 A RS20170790 A RS 20170790A RS P20170790 A RSP20170790 A RS P20170790A RS 56121 B1 RS56121 B1 RS 56121B1
- Authority
- RS
- Serbia
- Prior art keywords
- antagonists
- benzimidazole derivatives
- novel benzimidazole
- novel
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12195849 | 2012-12-06 | ||
| PCT/EP2013/075309 WO2014086739A1 (de) | 2012-12-06 | 2013-12-03 | Neuartige benzimidazolderivate als ep4-antagonisten |
| EP13798684.0A EP2928884B1 (de) | 2012-12-06 | 2013-12-03 | Neuartige benzimidazolderivate als ep4-antagonisten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS56121B1 true RS56121B1 (sr) | 2017-10-31 |
Family
ID=47325927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20170790A RS56121B1 (sr) | 2012-12-06 | 2013-12-03 | Novi derivati benzimidazola kao ep4-antagonisti |
Country Status (41)
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014012444B1 (pt) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9492460B2 (en) * | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| WO2014134267A1 (en) | 2013-02-27 | 2014-09-04 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| CA2925862A1 (en) | 2013-10-01 | 2015-04-09 | Glaxosmithkline Intellectual Property Development Limited | Compounds for affinity chromatography and for extending the half-life of a therapeutic agent |
| TW201607943A (zh) * | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
| DK3466949T3 (da) * | 2013-12-24 | 2021-03-15 | Bristol Myers Squibb Co | Tricyklisk forbindelse som anticancermidler |
| US9458156B2 (en) | 2014-12-23 | 2016-10-04 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． | 天然の併用ホルモン補充療法剤及び療法 |
| CN104326937B (zh) | 2014-09-03 | 2016-08-24 | 天津市肿瘤研究所 | 抗肿瘤化合物及其医药用途 |
| TW202140422A (zh) | 2014-10-06 | 2021-11-01 | 美商維泰克斯製藥公司 | 囊腫纖維化症跨膜傳導調節蛋白之調節劑 |
| US9725449B2 (en) | 2015-05-12 | 2017-08-08 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| CA3019380A1 (en) | 2016-03-31 | 2017-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP3435977A4 (en) | 2016-04-01 | 2019-10-16 | Therapeuticsmd, Inc. | PHARMACEUTICAL COMPOSITION OF STEROID HORMONE |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| CN109803962B (zh) | 2016-09-30 | 2022-04-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控蛋白的调节剂、以及药物组合物 |
| HUE052205T2 (hu) | 2016-12-09 | 2021-04-28 | Vertex Pharma | Cisztás fibrózis transzmembrán vezetõképesség szabályzó modulátora, gyógyszerészeti készítmények, kezelési eljárások és eljárás a modulátor elõállítására |
| WO2018162562A1 (en) * | 2017-03-10 | 2018-09-13 | Bayer Pharma Aktiengesellschaft | Use of an ep4 antagonist for the treatment of inflammatory pain |
| MA49128A (fr) | 2017-05-18 | 2021-03-17 | Idorsia Pharmaceuticals Ltd | Dérivés de pyrimidine utilisés en tant que modulateurs des récepteurs des pge2 |
| CA3063632A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as pge2 receptor modulators |
| TW201900180A (zh) | 2017-05-18 | 2019-01-01 | 瑞士商愛杜西亞製藥有限公司 | 嘧啶衍生物 |
| PE20191787A1 (es) | 2017-05-18 | 2019-12-24 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituidos |
| ES2893452T3 (es) | 2017-05-18 | 2022-02-09 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de PGE2 |
| US11253509B2 (en) | 2017-06-08 | 2022-02-22 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| BR112020000941A2 (pt) | 2017-07-17 | 2020-07-21 | Vertex Pharmaceuticals Incorporated | métodos de tratamento para fibrose cística |
| US11434201B2 (en) | 2017-08-02 | 2022-09-06 | Vertex Pharmaceuticals Incorporated | Processes for preparing pyrrolidine compounds |
| WO2019038156A1 (en) | 2017-08-22 | 2019-02-28 | Bayer Pharma Aktiengesellschaft | USE OF AN EP4 ANTAGONIST FOR THE TREATMENT OF ARTHRITIS |
| WO2019079760A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS |
| WO2019113476A2 (en) | 2017-12-08 | 2019-06-13 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| US11414439B2 (en) | 2018-04-13 | 2022-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| CN113301896A (zh) * | 2018-07-11 | 2021-08-24 | 阿瑞斯医疗有限公司 | Ep4抑制剂和其合成 |
| CN113527206B (zh) * | 2020-04-17 | 2022-12-30 | 上海中泽医药科技有限公司 | 一种苯并氮杂环类化合物、其制备方法及用途 |
| KR20230107228A (ko) | 2020-11-13 | 2023-07-14 | 오노 야꾸힝 고교 가부시키가이샤 | Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료 |
| US12016847B2 (en) | 2021-03-12 | 2024-06-25 | Bristol-Myers Squibb Company | Methods of treating prostate cancer |
| KR20230099093A (ko) * | 2021-12-27 | 2023-07-04 | 에이치케이이노엔 주식회사 | 벤즈이미다졸 유도체의 제조방법 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU763356C (en) | 1999-12-27 | 2004-08-26 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
| CN101934078A (zh) | 2000-01-18 | 2011-01-05 | 拜耳先灵医药股份有限公司 | 包含屈螺酮和雌激素的药物组合物及其应用 |
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| KR100592007B1 (ko) | 2002-04-12 | 2006-06-21 | 화이자 인코포레이티드 | Ｉｌ-６ 관련 질환 치료에서의 ｅｐ４ 수용체 리간드의용도 |
| MXPA05000812A (es) * | 2002-07-31 | 2005-04-19 | Euro Celtique Sa | Bencimidazoles aril sustituidos y su uso como bloqueadores del canal de sodio. |
| AU2002951247A0 (en) | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
| WO2004046143A1 (en) | 2002-11-15 | 2004-06-03 | Tibotec Pharmaceuticals Ltd. | Substituted indolepyridinium as anti-infective compounds |
| US6949564B2 (en) * | 2002-12-18 | 2005-09-27 | Pfizer Inc. | NPY-5 antagonists |
| KR101094003B1 (ko) | 2003-01-29 | 2011-12-15 | 아스터랜드 유케이 리미티드 | Ｅｐ4 수용체 길항제 |
| WO2004087690A2 (en) | 2003-04-03 | 2004-10-14 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the gaba-a receptor complex |
| TW200512147A (en) | 2003-07-25 | 2005-04-01 | Black Clawson Converting Machinery Inc | Method and apparatus for splicing webs |
| ES2441206T3 (es) | 2003-09-03 | 2014-02-03 | Raqualia Pharma Inc. | Compuestos de fenil o piridilamida como antagonistas de la prostaglandina E2 |
| BRPI0509993A (pt) | 2004-04-20 | 2007-10-16 | Pfizer Prod Inc | combinações compreendendo ligandos de alfa-2-delta |
| JP2008504233A (ja) | 2004-04-23 | 2008-02-14 | パラテック ファーマシューティカルズ インコーポレイテッド | 転写因子調節化合物およびその使用法 |
| CA2565660C (en) | 2004-05-04 | 2009-11-03 | Pfizer Inc. | Ortho substituted aryl or heteroaryl amide compounds |
| CN101142185A (zh) * | 2005-01-19 | 2008-03-12 | 比奥里波克斯公司 | 用于炎症治疗的吲哚 |
| JP5244091B2 (ja) | 2006-04-24 | 2013-07-24 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体アンタゴニストとしてのインドールアミド誘導体 |
| US7732447B2 (en) * | 2006-06-22 | 2010-06-08 | Cephalon, Inc. | Fused [d]pyridazin-7-ones |
| GB0614066D0 (en) * | 2006-07-14 | 2006-08-23 | Glaxo Group Ltd | Compounds |
| FR2904318B1 (fr) * | 2006-07-27 | 2011-02-25 | Scras | Derives de pyrimidinone et leur utilisation comme medicament |
| US8969394B2 (en) | 2006-08-11 | 2015-03-03 | Merck Frosst Canada Ltd. | Thiophenecarboxamide derivatives as EP4 receptor ligands |
| CA2679175C (en) | 2007-02-26 | 2015-01-13 | Merck Frosst Canada Ltd. | Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists |
| DE102007011105A1 (de) | 2007-03-02 | 2008-09-04 | Bayer Schering Pharma Aktiengesellschaft | Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose |
| EP2172447A4 (en) | 2007-07-03 | 2011-08-24 | Astellas Pharma Inc | amide |
| CN102026991A (zh) | 2007-08-09 | 2011-04-20 | 默沙东公司 | 制造噻吩甲酰胺衍生物的方法 |
| WO2010019796A1 (en) | 2008-08-14 | 2010-02-18 | Chemietek, Llc | Heterocyclic amide derivatives as ep4 receptor antagonists |
| US20100249125A1 (en) | 2009-03-31 | 2010-09-30 | The Texas A&M University System | Inhibition of prostglandin e2 receptors for the treatment of endometriosis |
| WO2010124097A2 (en) | 2009-04-22 | 2010-10-28 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
| JP6152643B2 (ja) * | 2010-02-22 | 2017-06-28 | 株式会社ＡｓｋＡｔ | Ｉｌ−２３媒介疾患を治療するためのｅｐ４受容体拮抗薬の使用 |
| TW201607943A (zh) * | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
-
2013
- 2013-03-12 UA UAA201506493A patent/UA115576C2/uk unknown
- 2013-12-03 BR BR112015012555-7A patent/BR112015012555B1/pt active IP Right Grant
- 2013-12-03 CN CN201380063594.4A patent/CN104854098B/zh active Active
- 2013-12-03 JP JP2015545771A patent/JP6367822B2/ja active Active
- 2013-12-03 MY MYPI2015701808A patent/MY175272A/en unknown
- 2013-12-03 RS RS20170790A patent/RS56121B1/sr unknown
- 2013-12-03 LT LTEP13798684.0T patent/LT2928884T/lt unknown
- 2013-12-03 PE PE2015000750A patent/PE20151065A1/es active IP Right Grant
- 2013-12-03 US US14/649,896 patent/US9708311B2/en active Active
- 2013-12-03 KR KR1020157017666A patent/KR20150092248A/ko active IP Right Grant
- 2013-12-03 DK DK13798684.0T patent/DK2928884T3/en active
- 2013-12-03 AP AP2015008463A patent/AP3862A/en active
- 2013-12-03 PT PT137986840T patent/PT2928884T/pt unknown
- 2013-12-03 ME MEP-2017-181A patent/ME02950B/me unknown
- 2013-12-03 EP EP13798684.0A patent/EP2928884B1/de active Active
- 2013-12-03 AU AU2013354226A patent/AU2013354226B2/en active Active
- 2013-12-03 CA CA2893630A patent/CA2893630C/en active Active
- 2013-12-03 MA MA38146A patent/MA38146B1/fr unknown
- 2013-12-03 WO PCT/EP2013/075309 patent/WO2014086739A1/de active Application Filing
- 2013-12-03 NZ NZ707825A patent/NZ707825A/en unknown
- 2013-12-03 SI SI201330742T patent/SI2928884T1/sl unknown
- 2013-12-03 EA EA201591087A patent/EA028830B1/ru not_active IP Right Cessation
- 2013-12-03 PL PL13798684T patent/PL2928884T3/pl unknown
- 2013-12-03 MX MX2015007135A patent/MX2015007135A/es active IP Right Grant
- 2013-12-03 ES ES13798684.0T patent/ES2637738T3/es active Active
- 2013-12-04 JO JOP/2013/0349A patent/JO3431B1/ar active
- 2013-12-06 UY UY0001035177A patent/UY35177A/es unknown
- 2013-12-06 AR ARP130104542A patent/AR093840A1/es unknown
- 2013-12-06 TW TW102144979A patent/TWI613198B/zh not_active IP Right Cessation
-
2015
- 2015-05-27 IL IL239026A patent/IL239026A0/en active IP Right Grant
- 2015-06-04 CL CL2015001508A patent/CL2015001508A1/es unknown
- 2015-06-04 CU CU2015000056A patent/CU20150056A7/es unknown
- 2015-06-05 CR CR20150296A patent/CR20150296A/es unknown
- 2015-06-05 GT GT201500138A patent/GT201500138A/es unknown
- 2015-06-05 TN TNP2015000250A patent/TN2015000250A1/fr unknown
- 2015-06-05 PH PH12015501289A patent/PH12015501289A1/en unknown
- 2015-06-05 NI NI201500077A patent/NI201500077A/es unknown
- 2015-06-05 EC ECIEPI201522555A patent/ECSP15022555A/es unknown
- 2015-10-29 HK HK15110717.4A patent/HK1210139A1/xx unknown
-
2017
- 2017-08-04 HR HRP20171200TT patent/HRP20171200T1/hr unknown
- 2017-08-10 CY CY20171100862T patent/CY1119200T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1210139A1 (en) | Novel benzimidazole derivatives as ep4 antagonists ep4 | |
| HRP20181429T1 (hr) | Novi derivati benzimidazola kao inhibitori kinaze | |
| EP2890691A4 (en) | BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS | |
| RS55684B1 (sr) | 2-(azaindol-2-il)benzimidazoli kao pad4 inhibitori | |
| EP2906040A4 (en) | NEW BENZIMIDAZOLE DERRAHYDROPYRANE DERIVATIVES | |
| IL238693A0 (en) | Tricyclic benzamidazoles are converted as kinase inhibitors | |
| EP2888007A4 (en) | NOVEL BENZIMIDAZOLTETRAHYDROFURANDERIVATE | |
| HK1223355A1 (zh) | 作為 配體的苯並咪唑衍生物 | |
| ME02576B (me) | Derivati tetrahidropirolotiazina kao inhibitori bace | |
| EP2818473A4 (en) | HETEROCYCLIC COMPOUND | |
| ZA201409497B (en) | Tetrahydroquinazolinone derivatives as parp inhibitors | |
| IL232503A (en) | H2 - Indazoles as antagonists of the ep2 receptor | |
| EP2685824A4 (en) | INDOLE DERIVATIVES USEFUL AS CCR2ANTAGONISTS | |
| SG11201404325VA (en) | Pyrimidooxazocine derivatives as mtor - inhibitors | |
| PL2814825T3 (pl) | Dihydrofuranowe pochodne azetydyny jako środki przeciwpasożytnicze |